MedTrace Logo

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

NCT02364076 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-12-13

Study results available
· View outcomes & findings →

Summary

This is a non-randomized clinical trial in patients with thymic carcinomas who failed prior systemic therapy. All subjects will receive pembrolizumab and epacadostat treatment in three week cycles until unacceptable toxicity, death, progressive disease or withdrawal.

Conditions

  • Thymic Carcinoma
  • Thymus Neoplasms
  • Thymus Cancer

Interventions

DRUG

Pembrolizumab

Administration of 200 mg MK-3475 once every 3 weeks

DRUG

Epacadostat

100mg taken by mouth twice daily

Sponsors & Collaborators

Principal Investigators

  • Giuseppe Giaccone, MD PhD · Georgetown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2019-06-30
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02364076 on ClinicalTrials.gov